PRIME’s technology for the development of novel veterinary vaccines
Boehringer Ingelheim and Biotech Startup enter a strategic collaboration
Prime Vector Technologies (PRIME), a Biotech Startup focusing on the development of viral vector based vaccines, and Boehringer Ingelheim, a leading global research-based pharmaceutical company, announce that they have entered a strategic collaboration, option and licence agreement. The collaboration is set to establish and test up to eight different vaccine candidates against a variety of veterinary diseases within the next three years using PRIME’s proprietary Orf virus (ORFV) platform technology.
Symbolic image
pixabay.com
ORFV platform
ORFV belongs to the family of poxviridae and possesses an excellent safety profile, stable expression of multiple transgenes simultaneously and is well suited for the possibility of multiple dose immunizations. Prior to the collaboration agreement, the platform was developed at the University of Tuebingen, and showed to be effective in various host animals against different infectious diseases. “After so many years of research and development on our platform, we are proud to receive the commitment to and trust in our technology from Boehringer Ingelheim as one of the world’s leading pharmaceutical companies in the animal health market. With this strong partner, we are excited to advance our technology and to enhance our contribution to improving animal health,” says Dr. Ralf Amann, CEO of PRIME.
Other news from the department business & finance
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.